文献速递基础与转化研究新药、器械与细胞基因治疗研发临床试验与 GCP

CAR-T细胞与T细胞疗法治疗癌症:转化科学综述

CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.
PubMed 文献 · JAMA · 2024-01-01

本综述总结CAR-T细胞疗法在血液肿瘤中的获批情况与疗效:6种产品获FDA批准用于6种血液恶性肿瘤,在大型B细胞淋巴瘤中4年总生存率54.6%优于标准化疗联合干细胞移植的46.0%;儿童急性淋巴细胞白血病3年随访48%存活且无复发。该疗法伴随细胞因子释放综合征(约40%–95%)和神经系统疾病(约15%–65%)等可逆急性毒性。

要点

  • 6种CAR-T产品获FDA批准用于6种血液恶性肿瘤。
  • 大型B细胞淋巴瘤中CAR-T较标准化疗联合移植改善4年总生存(54.6% vs 46.0%)。
  • 细胞因子释放综合征发生率约40%–95%,神经系统疾病约15%–65%。

核心结论

  • CAR-T细胞疗法是FDA批准的疗法,改善了多发性骨髓瘤的无进展生存和大型B细胞淋巴瘤的总生存,并在其他血液恶性肿瘤中达到高缓解率。
  • 新近批准的T淋巴细胞疗法在实体瘤中显示出改善结局的潜力。

研究设计与样本

  • 转化科学综述,总结CAR-T细胞及T细胞疗法的获批情况、疗效与毒性。

主要发现

  • 与标准化疗后干细胞移植相比,CAR-T细胞改善大型B细胞淋巴瘤患者4年总生存(54.6% vs 46.0%)。
  • 儿童急性淋巴细胞白血病患者经CAR-T细胞治疗达到持久缓解,3年随访时48%存活且无复发。
  • 既往接受1至4种非CAR-T细胞疗法的多发性骨髓瘤患者中,CAR-T细胞疗法较标准治疗延长无治疗缓解(1项试验中,CAR-T细胞疗法无进展生存13.3个月 vs 标准治疗4.4个月)。
  • CAR-T细胞疗法伴随可逆急性毒性:细胞因子释放综合征约40%至95%的患者,神经系统疾病约15%至65%。
  • T淋巴细胞疗法的常见不良事件为毛细血管渗漏综合征,表现为液体潴留、肺水肿和肾功能障碍。

关键数值与推荐

  • 6种CAR-T细胞产品获FDA批准用于6种血液恶性肿瘤:B细胞急性淋巴细胞白血病、大型B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤、慢性淋巴细胞白血病和多发性骨髓瘤。
  • 尚无CAR-T细胞疗法获FDA批准用于实体瘤,但近期另有2种T淋巴细胞疗法获批:1种用于黑色素瘤,1种用于滑膜细胞肉瘤。
  • 其他细胞疗法在部分实体瘤中达到缓解,包括儿童神经母细胞瘤、滑膜细胞肉瘤、黑色素瘤和人乳头瘤病毒相关癌症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chimeric antigen receptor (CAR) T cells are T lymphocytes that are genetically engineered to express a synthetic receptor that recognizes a tumor cell surface antigen and causes the T cell to kill the tumor cell. CAR T treatments improve overall survival for patients with large B-cell lymphoma and progression-free survival for patients with multiple myeloma. OBSERVATIONS: Six CAR T-cell products are approved by the US Food and Drug Administration (FDA) for 6 hematologic malignancies: B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Compared with standard chemotherapy followed by stem cell transplant, CAR T cells improved 4-year overall survival in patients with large B-cell lymphoma (54.6% vs 46.0%). Patients with pediatric acute lymphoblastic leukemia achieved durable remission after CAR T-cell therapy. At 3-year follow-up, 48% of patients were alive and relapse free. In people with multiple myeloma treated previously with 1 to 4 types of non-CAR T-cell therapy, CAR T-cell therapy prolonged treatment-free remissions compared with standard treatments (in 1 trial, CAR T-cell therapy was associated with progression-free survival of 13.3 months compared with 4.4 months with standard therapy). CAR T-cell therapy is associated with reversible acute toxicities, such as cytokine release syndrome in approximately 40% to 95% of patients, and neurologic disorders in approximately 15% to 65%. New CAR T-cell therapies in development aim to increase efficacy, decrease adverse effects, and treat other types of cancer. No CAR T-cell therapies are FDA approved for solid tumors, but recently, 2 other T lymphocyte-based treatments gained approvals: 1 for melanoma and 1 for synovial cell sarcoma. Additional cellular therapies have attained responses for certain solid tumors, including pediatric neuroblastoma, synovial cell sarcoma, melanoma, and human papillomavirus-associated cancers. A common adverse effect occurring with these T lymphocyte-based therapies is capillary leak syndrome, which is characterized by fluid retention, pulmonary edema, and kidney dysfunction. CONCLUSIONS AND RELEVANCE: CAR T-cell therapy is an FDA-approved therapy that has improved progression-free survival for multiple myeloma, improved overall survival for large B-cell lymphoma, and attained high rates of cancer remission for other hematologic malignancies such as acute lymphoblastic leukemia, follicular lymphoma, and mantle cell lymphoma. Recently approved T lymphocyte-based therapies demonstrated the potential for improved outcomes in solid tumor malignancies.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Brudno JN, Maus MV, Hinrichs CS, et al. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024. PMID: 39495525. doi:10.1001/jama.2024.19462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。